Hepac Health Economics in Prevention and Care 

About: Hepac Health Economics in Prevention and Care is an academic journal. The journal publishes majorly in the area(s): Public health & Health economics. It has an ISSN identifier of 1439-3972. Over the lifetime, 22 publications have been published receiving 462 citations.

What is it to be a model

Abstract: There are various ways in which data for economic evaluations may be obtained, including via clinical trials and via economic modelling. There are a number of advantages and disadvantages associated with each method, though generally clinical trials have been preferred to economic models, largely because they are believed to give a better indication of cost-effectiveness given their reliance on real, albeit clinical trial, data. This brief article discusses this view setting out the main arguments for and against this stance. The general conclusion reached being that while clinical trial data are used in most, if not all, economic evaluations modelling will inevitably also be required.

Pricing and Reimbursement Systems in Europe

Abstract: HEPAC 0•2000 8 Hardly another sector within the European Union is so individually structured as that of the health care systems. However, there is one thing they do all have in common: people working in the different health care systems have become much more costconscious in recent years. Those affected include: ◗ doctors, who in some countries have a predefined drug budget available to treat their patients and who face proceedings to recover the costs of the prescribed drugs if they exceed their budget ◗ sickness funds, which are faced with the task of financing new and often costly medicines or methods of treatment ◗ the pharmaceutical industry, which is currently facing long and difficult negotiations on prices and reimbursement for its products ◗ patients, who are involved in financing the health care system by way of out-of-pocket expenses or co-payments

Burden of illness imposed by osteoporosis in Germany

Abstract: Outre le poids que représente cette maladie pour l'individu, l'ostéoporose est la cause d'un investissement considérable de la part de la Santé Publique. Chaque année en Allemagne environ 3,5 à 4 Millions de journées d'hospitalisation sont dues à l'ostéoporose et à ses conséquences. En Allemagne les coûts annuels directs relatifs à cette maladie ont été d'environ 3,7 Milliards DM en 1997.La partie prépondérante des coûts concernait l'hospitalisation (plus de la moitié de tous les coûts, c'est-à-dire 2/3 des coûts directs). En outre les dépenses pour les soins des patients, qui représentent une part d'environ 17% des coûts directs, revêtent une importance significative. Du fait de l'âge le plus souvent élevé des patients, les coûts indirects, c'est-à-dire les pertes par rapport à la productivité, sont relativement insignificants. On estime que la charge due à l'ostéoporose est de ce fait souvent sous-estimée ou considérée comme une conséquence inévitable du vieillissement de la population allemande.Les principaux coûts concernent le traitement des fractures et les soins en découlant: c'est-à-dire que les séquelles de l'ostéoporose causées par les fractures prédominent das les coûts de la maladie. Il est clair que le traitment ambulatoire, y compris les coûts des médicaments, occasionne moins de frais que les soins à long-terme des patients qui ont eu des fractures.